

**NDA 22-081 Letairis® (ambrisentan)**

**RISK EVALUATION AND MITIGATION STRATEGY (REMS)**

Gilead Sciences, Inc.  
333 Lakeside Drive  
Foster City, CA 94404

**I. GOAL(S):**

The goals of the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program are:

1. To inform prescribers, patients, and pharmacists about the serious risk of teratogenicity and safe-use conditions for Letairis
2. To minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential (FRP) prescribed Letairis
  - a. Females who are pregnant must not be prescribed Letairis
  - b. Females taking Letairis must not become pregnant

**II. REMS ELEMENTS**

**A. Medication Guide**

A Medication Guide will be dispensed with each Letairis prescription in accordance with 21CFR 208.24.

The [Medication Guide](#) is part of the REMS and is appended.

**B. Elements To Assure Safe Use**

1. Healthcare providers who prescribe Letairis will be specially certified.
  - a. Gilead will ensure that physicians and other appropriately licensed healthcare professionals who prescribe Letairis are specially certified. Gilead will ensure that, to become certified, each prescriber agrees, on the *Prescriber Enrollment and Agreement Form*, that he or she has read the full prescribing information (PI), the *Letairis Medication Guide*, and the *Prescriber Guide to the Letairis REMS Program*. The physician further agrees that he or she will:
    - i) Enroll all females in the Letairis REMS program
    - ii) Determine whether each female is of reproductive potential as defined in the *Prescriber Guide to the Letairis REMS Program*

- iii) Advise all females that Letairis is only available through a restricted distribution program called the Letairis REMS program
- iv) For FRP:
  - (1) Educate FRPs about the risk of teratogenicity, the need to use highly reliable contraception as defined in the *Prescriber Guide to the Letairis REMS Program* during Letairis treatment and for one month following treatment discontinuation, and the need to use emergency contraception if required
  - (2) Order and review pregnancy tests prior to initiation of Letairis treatment, monthly during treatment, and for one month after stopping Letairis treatment
  - (3) Counsel a female patient if she is not complying with the required testing or if she is not using appropriate contraception as specified for FRP
  - (4) Review with FRP, the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* prior to initiating treatment
  - (5) Report any changes in reproductive status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change
- v) For Pre-Pubertal Females:
  - (1) Educate Pre-Pubertal Female patient and parent/guardian about the risk of teratogenicity
  - (2) Review the *Letairis Medication Guide* with the patient and parent/guardian
  - (3) Regularly evaluate Pre-Pubertal Females for any change in reproductive status while receiving Letairis
  - (4) Verify and document status as Pre-Pubertal Female at least annually for Pre-Pubertal Females who are at least 8 years of age and older by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
  - (5) Report any change in reproductive status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change
- vi) For Post-Menopausal Females:
  - (1) Report any misclassification in reproductive potential status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware.

- (2) Report adverse events and any pregnancies during Letairis treatment to Gilead with all available information required for the Form FDA 3500A
- vii) For Females with Other Medical Reasons for Permanent, Irreversible Infertility:
- (1) Report any misclassification in reproductive potential status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware.
  - (2) Report adverse events and any pregnancies during Letairis treatment to Gilead with all available information required for the Form FDA 3500A
- b. Gilead will:
- i) Ensure that prescribers' enrollment information and date of agreement are linked to their enrolled female patients' information in a validated database
  - ii) For all females, ensure that the patient information from a new prescriber is linked in the Letairis REMS program database with information from the prior prescriber
  - iii) Ensure that the Letairis REMS Coordinating Center annually contacts the prescriber of a Pre-Pubertal Female to ensure that the prescriber verifies the Pre-Pubertal Female's reproductive status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
  - iv) Maintain a validated database of certified prescribers in the Letairis REMS program. Gilead will ensure that prescribers' certification requirements are met and may de-enroll noncompliant prescribers until the requirements are met
  - v) Ensure that within 60 days of REMS modification approval, all materials listed in or appended to the Letairis REMS will be available through the Letairis REMS program website ([www.letairisrems.com](http://www.letairisrems.com)) or by calling the Letairis REMS Coordinating Center at 1-866-664-5327
- c. The following materials are part of the Letairis REMS program and are appended:
- i) *Prescriber Enrollment and Agreement Form*
  - ii) *Prescriber Guide to the Letairis REMS Program*
  - iii) *Letairis REMS Program Guide for Females Who Can Get Pregnant*
  - iv) *Patient Enrollment and Consent Form*
  - v) *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
  - vi) *Letairis REMS website ([www.letairisrems.com](http://www.letairisrems.com))*

2. Pharmacies, practitioners, and health care settings that dispense Letairis (dispensers) will be specially certified.
  - a. Gilead will ensure that pharmacies, practitioners, and health care settings that dispense Letairis are specially certified. Gilead will ensure that, to be certified, pharmacies, practitioners, and health care settings that dispense Letairis attest that:
    - i) For all female patients, they will dispense Letairis only to patients enrolled in the Letairis REMS program
    - ii) Certified pharmacies will dispense Letairis to female patients only after receipt of patient enrollment form from the Letairis REMS Coordinating Center
    - iii) Certified pharmacies will confirm any change in a female patient's reproductive potential status through the Letairis REMS Coordinating Center
    - iv) Provide a *Letairis Medication Guide* to patients each time Letairis is dispensed
    - v) For FRP (as defined in the *Prescriber Guide to the Letairis REMS Program*):
      - (1) Counsel FRP on the risk of serious birth defects and the need to use highly reliable contraception (as defined in the *Prescriber Guide to the Letairis REMS Program*) during Letairis treatment and for one month after stopping Letairis treatment
      - (2) Inform FRP of the need to complete a monthly pregnancy test and to inform their prescriber immediately if they suspect they may be pregnant
      - (3) Speak with each FRP, or their prescriber, every month before dispensing Letairis to obtain confirmation that pregnancy testing was completed
      - (4) Dispense Letairis to FRP no more than a 30-day supply and only upon completing the following process:
        - (a.) Obtain confirmation from FRP that the pregnancy testing was completed
        - (b.) If unable to obtain confirmation from FRP that the pregnancy testing was completed, or if the FRP cannot be reached, the certified pharmacy will obtain confirmation from the patient's prescriber
        - (c.) If the prescriber for the FRP cannot confirm that the pregnancy testing was completed, the certified pharmacy will:
          - i. Remind the prescriber of his/her obligation to order and review monthly pregnancy tests

- ii. Ask the prescriber whether or not he/she authorizes the refill of Letairis. The FRP is eligible to receive a 30-day supply of Letairis only if the prescriber authorizes the refill of Letairis
    - vi) Notify Gilead of reports of adverse events and any reports of pregnancy and provide all available information needed for FDA Form 3500A
    - vii) Certified pharmacies will provide daily product dispensing data for FRP to the Letairis REMS Coordinating Center
  - b. Gilead will ensure the Letairis REMS Coordinating Center notifies certified pharmacies of patients' change in reproductive status within one business day of receipt of completed *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
  - c. Gilead will ensure that a designated representative of each certified pharmacy:
    - i) Is trained on the requirements of the Letairis REMS program
    - ii) Trains dispensing staff on the Letairis REMS program procedures and Letairis REMS materials as described above prior to dispensing Letairis to FRP
    - iii) Agrees that the certified pharmacy may be audited by the FDA, Gilead, or a third party designated by Gilead
3. Letairis will be dispensed to FRP with evidence or other documentation of safe-use conditions:
- a. Gilead will ensure that FRP treated with Letairis are enrolled in the Letairis REMS program and assigned a unique patient identification number, before Letairis is dispensed by a certified pharmacy. Gilead will ensure that, to become enrolled, or when changing prescribers, each FRP must sign a *Patient Enrollment and Consent Form* acknowledging that she has read the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant*. By enrolling, the FRP agrees:
    - i) To be contacted, prior to each shipment of Letairis, to obtain confirmation that pregnancy testing was completed
    - ii) To be counseled on the requirements of the Letairis REMS program and the risks of Letairis
    - iii) To be contacted by Gilead or the Letairis REMS Coordinating Center if she becomes pregnant while on Letairis or within 30 days after treatment discontinuation

### **C. Implementation System**

The Implementation System will include the following:

1. Gilead will maintain a validated database of certified dispensers and females enrolled in the Letairis REMS program to monitor and evaluate implementation of the elements provided for under Sections B.2 and B.3 above
2. Gilead will monitor the distribution of Letairis to ensure that the drug is only shipped to certified dispensers.
3. Gilead will track Letairis dispensing and review the location and amount of medication dispensed by certified pharmacies to FRPs.
4. Gilead will audit all certified pharmacies and the Letairis REMS Coordinating Center at the initiation of the Letairis REMS program to ensure they implement the program as directed. Thereafter, Gilead will include the certified pharmacies and the Letairis REMS Coordinating Center in the company's annual audit plan
5. Gilead will monitor and evaluate the implementation of the elements provided for under Sections B.1, B.2, and B.3, above, in the manner described in the Letairis REMS Supporting Document, and take reasonable steps to work to improve implementation of these elements
6. Gilead will monitor the certified pharmacies to ensure their compliance with the Letairis REMS program and will institute corrective actions if they are found non-compliant

**D. Timetable for Submission of Assessments**

Gilead will submit Letairis REMS assessments to the FDA annually no later than August 13th. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that REMS assessment. Gilead will submit each REMS assessment so that it will be received by the FDA on or before the due date.

# Letairis Risk Evaluation and Mitigation Strategy (REMS) Program

## Prescriber Enrollment and Agreement Form

To be enrolled into the Letairis REMS Program, complete and fax this form.

**FAX THIS FORM TO:** 1-888-882-4035

---

### 1 Prescriber Information

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_

Suffix: \_\_\_\_\_

Specialty: \_\_\_\_\_ Name of Facility: \_\_\_\_\_

Office Contact (First and Last Name): \_\_\_\_\_

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

E-mail: \_\_\_\_\_ Phone: (\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_) \_\_\_\_\_

State License #: \_\_\_\_\_ NPI #: \_\_\_\_\_

---

### 2 Prescriber Agreement

By signing below, you signify your understanding of the risks of Letairis® (ambrisentan) treatment and your obligation as a Letairis prescriber to educate your female patients about these risks, counsel them on risk reduction, monitor them appropriately, and report adverse events to the Letairis REMS Coordinating Center. Specifically, you attest to the following:

- I have read the full Prescribing Information, the *Letairis Medication Guide*, and the *Prescriber Guide for the Letairis REMS Program* and agree to comply with the Letairis REMS Program requirements
- I agree to enroll all female patients into the Letairis REMS Program
- I will determine the reproductive potential status of all female patients using the definitions provided in the *Prescriber Guide for the Letairis REMS Program*
- I will advise all female patients that Letairis is only available through a restricted distribution program called the Letairis REMS Program
- I will counsel Females of Reproductive Potential on the risks of Letairis, including the risk of serious birth defects, and review the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* with the patient
- I will counsel the Pre-Pubertal Female patient and parent/guardian on the risks of Letairis, including the risk of serious birth defects, and review the *Letairis Medication Guide* with the patient and parent/guardian
- I will verify the reproductive potential status annually for Pre-Pubertal Females who are 8 years of age and older
- I will order and review pregnancy tests for Females of Reproductive Potential prior to initiating treatment with Letairis, monthly during treatment, and for 1 month after stopping treatment
- I agree to report any change in reproductive potential status by submitting a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change
- I will counsel Females of Reproductive Potential to use highly reliable contraception during Letairis treatment, and for 1 month after stopping treatment, and the need to use emergency contraception if required
- I will counsel female patients who fail to comply with the Letairis REMS Program requirements
- I will notify the Letairis REMS Coordinating Center of any adverse events, or if any patient becomes pregnant during Letairis treatment or within 1 month after stopping treatment

<b>REQUIRED</b>	Prescriber Signature: X	Date:
-----------------	----------------------------	-------

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call **1-866-664-5327** for more information about the Letairis REMS Program.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0015 October 2015  
Letairis is a registered trademark of Gilead Sciences, Inc.  
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.



# Prescriber Guide for the Letairis REMS Program

Changes to the Letairis Risk Evaluation and Mitigation Strategy (REMS)  
Program (October 2014)

- New definition of Female of Non-Reproductive Potential (page 4)
- Revised form: *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* (page 6)

This guide is part of an FDA-approved REMS.



**Letairis**<sup>®</sup>  
ambrisentan  
*5 mg and 10 mg Tablets*

# Table of Contents

Letairis REMS Program .....	2
Overview of the Letairis REMS Program .....	3
Summary of the Letairis REMS Program Requirements by Patient Category .....	3
Your Role in the Letairis REMS Program.....	4
Contraceptive Options for Females of Reproductive Potential.....	7
Role of Certified Pharmacies .....	9
The Letairis REMS Coordinating Center.....	9

# Letairis REMS Program

## Indication

Letairis is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1):

- To improve exercise ability and delay clinical worsening.
- In combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability.

Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).

## Risk of teratogenicity

Letairis is contraindicated in females who are pregnant, as Letairis may cause fetal harm when administered to a pregnant female. There are no data regarding the use of Letairis in pregnant females; the possibility of serious birth defects in humans cannot be excluded.

Pregnancy must be excluded prior to the initiation of Letairis treatment, monthly thereafter, and for 1 month after stopping treatment.

## Letairis REMS Program

Because of the risk of serious birth defects, Letairis is only available to females through a restricted distribution program under an FDA-required REMS. The Letairis REMS Program helps ensure the benefits of Letairis outweigh the risk of teratogenicity. The purposes of the Letairis REMS Program are to:

- Inform and educate healthcare providers and female patients about the risk of teratogenicity associated with the use of Letairis
- Minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential
  - Females who are pregnant must not be prescribed Letairis
  - Females taking Letairis must not become pregnant

## Changes to the Letairis REMS Program

- New definition of Females of Non-Reproductive Potential

- Revised form: *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*

## Overview of the Letairis REMS Program

- Letairis is only available to females through a restricted distribution program
- Prescribers must enroll in the Letairis REMS Program and comply with the Letairis REMS Program requirements to prescribe Letairis
- All female patients must enroll in the Letairis REMS Program to receive Letairis
- Prescribers must educate and counsel Females of Reproductive Potential and Pre-Pubertal Females on the risks of Letairis, including the risk of serious birth defects. The parent/guardian of the Pre-Pubertal Female must also be educated and counseled on the risks of Letairis.
- Prescribers must order and review pregnancy tests for Females of Reproductive Potential prior to initiation of treatment, monthly during treatment, and for 1 month after stopping treatment

## Summary of the Letairis REMS Program Requirements by Patient Category

Requirement	Female of Reproductive Potential	Female of Non-Reproductive Potential		
		Pre-Pubertal	Post-Menopausal	Other medical reasons for permanent, irreversible infertility
Prescriber enrolls female patients into Letairis REMS Program	X	X	X	X
Counseling with <i>Letairis REMS Program Guide for Females Who Can Get Pregnant</i>	X			
Counseling with <i>Letairis Medication Guide</i> , including the risk of teratogenicity	X	X*		
Prescriber must order and review pregnancy tests prior to initiation of treatment, monthly during treatment, and for 1 month after stopping treatment	X			
Prescriber must verify reproductive status annually by completing the <i>Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form</i> for females who are at least 8 years of age and older		X		

Prescriber must complete the <i>Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form</i> upon becoming aware of any change in reproductive potential status within 10 business days of awareness	X	X	X	X
---	---	---	---	---

\* **Counsel Pre-Pubertal Female patient and parent/guardian**

## Your Role in the Letairis REMS Program

Prescribers must complete the following steps in the Letairis REMS Program:

- 1. Read the Letairis Prescribing Information and this guide to understand the Letairis REMS Program and the risks of Letairis**
- 2. Complete the *Prescriber Enrollment and Agreement Form***
  - You will attest to understanding the risks of Letairis and agree to comply with the requirements of the Letairis REMS Program
- 3. Determine the reproductive potential status of female patients**

### **Females of Reproductive Potential:**

- Females of Reproductive Potential include girls who have entered puberty and all women who have a uterus and have not passed through Menopause (as defined in the following column)
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal)

### **Females of Non-Reproductive Potential:**

- Pre-Pubertal Females:** Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
- Post-Menopausal Females:** Females who have passed through Menopause (as defined below)
- Females with other medical reasons for permanent, irreversible infertility**

### **Definition of Menopause:**

- Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy

### **4. Educate/counsel all female patients about risks of Letairis and about the Letairis REMS Program**

- Advise all females that Letairis is only available through a restricted distribution program called the Letairis REMS Program

### **For Females of Reproductive Potential:**

- Review with the Female of Reproductive Potential the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* prior to initiating treatment
- Educate Females of Reproductive Potential about the risk of teratogenicity, the need to use highly reliable contraception (see page 7) during Letairis treatment and for 1 month following treatment discontinuation, and the need to use emergency contraception, if required
- Order and review pregnancy tests prior to initiation of Letairis treatment, monthly during treatment, and for 1 month after stopping Letairis treatment
- Advise the patient of the requirement for monthly pregnancy tests to confirm they are not pregnant so they can receive Letairis
- Counsel the Female of Reproductive Potential if she is not complying with the Letairis REMS Program requirements
- Submit a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of any change in reproductive potential status

### **For Females of Non-Reproductive Potential:**

#### **For Pre-Pubertal Females:**

- Educate the Pre-Pubertal Female patient and parent/guardian about the risk of teratogenicity and review the *Letairis Medication Guide* with the patient and parent/guardian
- Evaluate regularly Pre-Pubertal Females for any changes in reproductive status while receiving Letairis
- Verify the reproductive potential status annually for Pre-Pubertal Females who are at least 8 years of age and older by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
- Report any misclassification or change in reproductive potential status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change

#### **For Post-Menopausal Females:**

- Report any misclassification in reproductive potential status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual*

*Verification Form* within 10 business days of becoming aware

**For females with other medical reasons for permanent, irreversible infertility:**

- Report any misclassification in reproductive potential status by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware

## 5. Check pregnancy status (in Female of Reproductive Potential)

- Order and review pregnancy tests for the patient:
  - Prior to initiating treatment
  - Monthly during treatment
  - 1 month after stopping treatment

The patient must agree to be contacted by the Certified Pharmacy prior to each shipment to confirm that a pregnancy test was completed, and she must also agree to be contacted by the Letairis REMS Coordinating Center if she becomes pregnant while on Letairis or within 1 month of stopping treatment.

## 6. Enroll all female patients into the Letairis REMS Program

- Complete a *Letairis Patient Enrollment and Consent Form*
- Confirm the female patient has agreed to comply with program requirements and has signed the form where indicated. Fax the completed form, along with all patient insurance information, including prescription drug benefits and medical benefits, to the Letairis REMS Coordinating Center at **1-888-882-4035**
- Keep the original form with the patient's records

## 7. Evaluate reproductive potential status of female patients throughout treatment

- Report any change in patient's reproductive potential status within 10 business days of becoming aware of the change to the Letairis REMS Coordinating Center by faxing the completed *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* to **1-888-882-4035**
- Verify the reproductive potential status of Pre-Pubertal Females who are 8 years of age or older annually by completing the *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*
- Counsel females who fail to comply with the Letairis REMS Program requirements
- Notify the Letairis REMS Coordinating Center of any adverse events, or if any patient becomes pregnant during Letairis treatment or within 1 month of stopping treatment


## Contraceptive Options for Females of Reproductive Potential

- All Females of Reproductive Potential should undergo contraceptive counseling with either the prescriber or another designated healthcare practitioner trained in contraceptive counseling

Please refer to the diagram on the next page for a complete list of the acceptable contraceptive options. The same diagram also appears in the *Letairis REMS Program Guide for Females Who Can Get Pregnant* and should be used to discuss acceptable birth control options with patients.

- Educate and counsel Females of Reproductive Potential on the use of emergency contraception in the event of unprotected sex or known or suspected contraceptive failure
- Remind patients to report to you immediately any delay in having a period or any other reason of suspected pregnancy during treatment
- If pregnancy is suspected for any reason, a pregnancy test must be performed
- **The prescriber must notify the Letairis REMS Coordinating Center (by phone at 1-866-664-5327) of any pregnancies that occur during treatment or within 1 month of discontinuation**

## Contraceptive Options for Females of Reproductive Potential



## Role of Certified Pharmacies

- Contact all Females of Reproductive Potential receiving Letairis each month to confirm completion of pregnancy testing, and counsel them on the risk of teratogenicity
- Provide a copy of the *Medication Guide* to patients/caregivers each time Letairis is dispensed
- Ship Letairis to the patient/caregiver

For a list of Certified Pharmacies, visit [www.letairisrems.com](http://www.letairisrems.com) or call the Letairis REMS Coordinating Center at **1-866-664-5327**

## The Letairis REMS Coordinating Center

- Enters every Letairis prescriber and female patient into the Letairis REMS Program database
- Collects all *Patient Enrollment and Consent Forms* and *Prescriber Enrollment and Agreement Forms*
- Sends patient information to the chosen Certified Pharmacy
- Collects information about adverse events, changes in reproductive status, annual verification of reproductive potential status for Pre-Pubertal Females, and any occurrences of pregnancies during Letairis treatment or within 1 month of treatment discontinuation



### **Additional questions**

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call the Letairis REMS Coordinating Center at 1-866-664-5327 for more information about the Letairis REMS Program.

Please see the accompanying patient Medication Guide and full Prescribing Information, including **BOXED WARNING**, for more complete information.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0016 OCTOBER 2015  
Letairis is a registered trademark of Gilead Sciences, Inc.  
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.



LETAIRIS RISK EVALUATION AND MITIGATION STRATEGY  
(REMS)

# Letairis REMS Program Guide for Females Who Can Get Pregnant

This guide is part of an FDA-approved REMS.

Reference ID: 3828639



**Letairis<sup>®</sup>**  
*ambrisentan*  
5 mg and 10 mg Tablets

# Table of Contents

## Information for Females Who Can Get Pregnant

What is Letairis? .....	2
What are the serious risks of Letairis? .....	2
What is the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program? .....	2
How do I enroll in the Letairis REMS Program? .....	3
What are the Letairis REMS Program requirements for me? .....	3
What are my birth control options? .....	4
How will I receive my Letairis? .....	6

# Information for Females Who Can Get Pregnant

## What is Letairis?

Letairis is a prescription medicine to treat pulmonary arterial hypertension (PAH), which is high blood pressure in the arteries of your lungs. Letairis can improve your ability to exercise and it can help slow down the worsening of your physical condition and symptoms.

## What are the serious risks of Letairis?

**Letairis can cause serious birth defects if taken during pregnancy.** Females must not be pregnant when they start taking Letairis or become pregnant while taking Letairis, or for 1 month after stopping Letairis.

## What is the Letairis Risk Evaluation and Mitigation Strategy (REMS) Program?

Because of the risk of serious birth defects, the FDA has required a special program called a Risk Evaluation and Mitigation Strategy (REMS) for Letairis. The purpose of the Letairis REMS Program is to make sure the benefits of Letairis outweigh the risks. All females must enroll in the Letairis REMS Program to receive Letairis. Specific requirements apply to females who can get pregnant.

To receive Letairis:

- 1) You must talk with your doctor to ensure the benefits outweigh the risks of Letairis
- 2) You must agree to all of the requirements of the Letairis REMS Program. These requirements include monthly pregnancy tests and use of appropriate birth control while taking Letairis and for 1 month after stopping Letairis
- 3) Your doctor will enroll you in the Letairis REMS Program
- 4) Your prescription will be mailed to you from a Certified Pharmacy that you and your doctor will choose

## How do I enroll in the Letairis REMS Program?

Follow these steps with your doctor:

- Read all the patient information about Letairis and the Letairis REMS Program included in this guide or on the Letairis REMS Program website, [www.letairisrems.com](http://www.letairisrems.com)
- Talk with your doctor to ensure the benefits outweigh the risks of Letairis
- Ask questions. Make sure you understand what you need to do to enroll and take part in the Letairis REMS Program. Make sure you know how to receive and take Letairis
- You and your doctor choose a Certified Pharmacy to supply Letairis. In some cases your insurance company may need you to use a specific Certified Pharmacy
- You and your doctor fill out the *Patient Enrollment and Consent Form*. After you read and sign it, your doctor sends it to the Letairis REMS Coordinating Center

## What are the Letairis REMS Program requirements for me?

You are considered to be a female who can get pregnant if you have entered puberty, have a uterus, and have not passed through Menopause.

To receive Letairis, you must:

- Have a negative pregnancy test before you start taking Letairis and before you receive your refills. Your doctor orders the pregnancy tests for you. Your Certified Pharmacy will call you and ask if you have taken this test before shipping your refill
- **Be sure you take your monthly pregnancy tests as ordered by your doctor. You may not receive your Letairis refill on time if you do not take your monthly pregnancy tests**

Do not have unprotected sex. Use appropriate birth control during your Letairis treatment and for 1 month after stopping your Letairis treatment because the medicine may still be in your body. Page 5 of this guide shows your birth control options.


Talk to your doctor or pharmacist right away if you have unprotected sex, if you think your birth control has failed, or if you think you may be pregnant. Your doctor may tell you to use emergency birth control. Do not wait until your next appointment to tell your doctor if you miss your menstrual period or if you think you may be pregnant.

### **What are my birth control options?**

Your doctor will talk to you about your birth control options. Use the diagram on the next page to help decide what birth control options are best for you. Talk to your doctor if you have questions about your birth control options. Tell your doctor if you want to change your birth control method.

You may choose from the four options listed on the next page. More than one birth control method might be needed every time you have sex (intercourse).

## Your birth control options



## How will I receive my Letairis?

Certified Pharmacies provide products and services for patients with certain diseases. Only Certified Pharmacies can provide Letairis to you. In some cases, your insurance company may require you to use a specific Certified Pharmacy.

Your Certified Pharmacy ships your Letairis refill to you. Before each shipment, you will be called to confirm that you have taken a monthly pregnancy test before refilling your prescription. **It is important that your Certified Pharmacy is able to contact you in order to avoid delays in your refills.**

For a list of participating Certified Pharmacies, visit [www.letairisrems.com](http://www.letairisrems.com).

If you have questions or concerns about Letairis, talk to your doctor. Please visit [www.letairisrems.com](http://www.letairisrems.com) or call **1-866-664-5327** for more information about the Letairis REMS Program.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0017 OCTOBER 2015  
Letairis is a registered trademark of Gilead Sciences, Inc.  
Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.



# Letairis Patient Enrollment and Consent Form

Fax this form and all patient insurance information, including drug benefit cards (front and back), to:  
1-888-882-4035

## 1 Specialty Pharmacy

Select a preferred Certified Pharmacy:

Accredo  Aetna Specialty Pharmacy  CIGNA Tel-Drug  CuraScript  CVS Caremark  Exactus Pharmacy  
Solutions  Kaiser Specialty Pharmacy  OptumRx  RightSource Specialty Pharmacy  Walgreens Specialty  
Pharmacy

## 2 Patient Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Birthdate: \_\_\_\_/\_\_\_\_/\_\_\_\_ Gender:  M  F Preferred Time to Contact:  Day  Evening  
Phone: (\_\_\_\_) \_\_\_\_\_ Alternate Phone: (\_\_\_\_) \_\_\_\_\_ E-mail: \_\_\_\_\_  
Alternate Contact Name: \_\_\_\_\_ Phone: (\_\_\_\_) \_\_\_\_\_  
Relationship: \_\_\_\_\_

## 3 Written Permission to Share Information

I allow my healthcare providers and health plans to share personal and medical information about me with Gilead and its agents and contractors ("Gilead"). I allow Gilead to use and share this information to: 1) communicate with me, my healthcare providers and health plans about my medical care; 2) provide support services, including providing Letairis® (ambrisentan) to me and planning laboratory testing for me; 3) learn how well Letairis, the Letairis REMS, or LEAP program is working; and 4) contact me so that I may receive educational materials about Letairis, the Letairis REMS, or the LEAP program.

Once my health information has been shared with Gilead, federal privacy laws may no longer protect it. This means that Gilead can give it to others, such as the Food and Drug Administration (FDA), to learn if the Letairis REMS Program is being run properly as required by law. I understand that my pharmacy may receive payment in connection for disclosing my health information to Gilead for the purposes allowed under this authorization. I may also cancel my permission at any time by writing a letter to Gilead and faxing to 1-888-882-4035 or by calling 1-866-664-5327. If I cancel, Gilead will stop using or sharing my information for the reasons listed above, except as required by law to end my participation in the Letairis REMS Program. If I am a female and not enrolled in the Letairis REMS Program, I will no longer be able to receive Letairis. If I do not sign this form, I understand my eligibility for health plan benefits and treatment by my doctor will not change. I am allowed a copy of this signed agreement. My written permission ends 10 years from the date I signed it.

<b>REQUIRED FOR ALL PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
----------------------------------	---	-------------

## 4 Female Patient Agreement

For all Females: I acknowledge that I have been counseled that Letairis is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).

For Females Who Can Get Pregnant: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects. I have read the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant*. I understand that I will be contacted by Gilead and/or its agents and contractors to receive counseling on the risk of serious birth defects and the importance of not becoming pregnant, ensure that I have completed pregnancy testing before I start Letairis, monthly before each refill, and for 1 month after stopping Letairis, and obtain information about my pregnancy, if I become pregnant.

For Pre-Pubertal Females: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects, and that I have read the *Letairis Medication Guide*. Parent or guardian must sign below.

<b>REQUIRED FOR ALL FEMALE PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
---	---	-------------

## 5 Prescriber Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Phone: (\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_) \_\_\_\_\_ NPI #: \_\_\_\_\_  
Office Contact (First and Last Name): \_\_\_\_\_ E-mail: \_\_\_\_\_

## 6 Prescription

LETAIRIS:  5 mg tablets (30 tablets)  10 mg tablets (30 tablets)  PO  QD Refills: \_\_\_\_\_

Instructions: \_\_\_\_\_

Ship to:  Patient Home (address listed above)  Prescriber Office (address listed above)  Other (please indicate below)

Name: \_\_\_\_\_ Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_ Phone: \_\_\_\_\_  
(\_\_\_\_) \_\_\_\_\_

## 7 Statement of Medical Necessity

**Diagnosis: Pulmonary Arterial Hypertension** (This is for insurance purposes only, not to suggest approved uses or indications. Please select one category below.)

Familial (ICD 416.0)  Idiopathic (ICD 416.0)

Scleroderma (ICD 710.1)  HIV (ICD 042 \_\_\_\_\_)

Lupus (ICD 710.0)  Portal Hypertension (ICD 572.3)

Congenital Heart Defects (ICD 745. \_\_\_\_\_)  Other: \_\_\_\_\_ (ICD \_\_\_\_\_)

## 8 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below Only 1 box should be checked. (Please see definitions of these terms on the following page)

### Female of Reproductive Potential

Has a negative pregnancy test been confirmed prior to prescribing Letairis?

Yes

No

OR

### Female of Non-Reproductive Potential (choose one below)

Pre-Pubertal Female

Post-Menopausal Female

Other medical reasons for permanent, irreversible infertility

I certify that for female patients, I have provided the appropriate counseling and Letairis REMS materials, and I will continue to fulfill my obligations under the Letairis REMS Program as outlined on page 2 of this form.

By signing, I certify that the above therapy is medically necessary.

<b>REQUIRED FOR ALL PRESCRIBERS</b>	Prescriber Signature: X	Date:
-------------------------------------	----------------------------	-------

## 8 Prescriber Authorization (continued)

### Definitions

#### Females of Reproductive Potential

- Females of Reproductive Potential include girls who have entered puberty and all women who have a uterus and have not passed through Menopause (as defined below).
- For the purposes of REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

#### Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
- Post-Menopausal Females: Females who have passed through Menopause (as defined below)
- Other medical reasons for permanent, irreversible infertility

#### Menopause

Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or postsurgical from bilateral oophorectomy.

### Prescriber obligations under the Letairis REMS Program

#### For All Females

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Letairis is available only through a restricted distribution program under an FDA-required REMS.
- I will evaluate the patient and agree to document any change in reproductive potential status by submitting a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

#### For Females of Reproductive Potential

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* with the patient (and parent/guardian when appropriate).
- I will order and review pregnancy tests prior to initiation of Letairis treatment, monthly during treatment, and for 1 month after stopping treatment in accordance with the Letairis REMS Program.

#### For Pre-Pubertal Females

- I acknowledge that I have counseled the patient and parent/guardian on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* with the patient and parent/guardian.
- I will evaluate the patient's reproductive potential status, verify reproductive potential status annually for Pre-Pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive potential status on a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

## 9 Fax this enrollment form and all patient insurance information, including drug benefit cards (front and back), to 1-888-882-4035.

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call **1-866-664-5327** for more information about the Letairis REMS Program.

Please see accompanying patient Medication Guide and full Prescribing Information, including **BOXED WARNING**.

This form is part of an FDA-approved REMS.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0018 OCTOBER 2015  
Letairis are registered trademarks of Gilead Sciences, Inc. Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.

# Letairis Patient Enrollment and Consent Form

Enroll Patient in *LabSync*<sup>®</sup>:  Yes  No

Fax this form and all patient insurance information, including drug benefit cards (front and back), to:  
1-888-882-4035

## 1 Specialty Pharmacy

Select a preferred Certified Pharmacy:

Accredo  Aetna Specialty Pharmacy  CIGNA Tel-Drug  CuraScript  CVS Caremark  Exactus Pharmacy  
Solutions  Kaiser Specialty Pharmacy  OptumRx  RightSource Specialty Pharmacy  Walgreens Specialty  
Pharmacy

## 2 Patient Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Birthdate: \_\_\_\_/\_\_\_\_/\_\_\_\_ Gender:  M  F Preferred Time to Contact:  Day  Evening  
Phone: (\_\_\_\_) \_\_\_\_\_ Alternate Phone: (\_\_\_\_) \_\_\_\_\_ E-mail: \_\_\_\_\_  
Alternate Contact Name: \_\_\_\_\_ Phone: (\_\_\_\_) \_\_\_\_\_  
Relationship: \_\_\_\_\_

## 3 Written Permission to Share Information

I allow my healthcare providers and health plans to share personal and medical information about me with Gilead and its agents and contractors ("Gilead"). I allow Gilead to use and share this information to: 1) communicate with me, my healthcare providers and health plans about my medical care; 2) provide support services, including providing Letairis<sup>®</sup> (ambisentan) to me and planning laboratory testing for me; 3) learn how well Letairis, the Letairis REMS, or LEAP program is working; and 4) contact me so that I may receive educational materials about Letairis, the Letairis REMS, or the LEAP program.

I understand that I may choose not to take part in *LabSync*, but I may still take part in Letairis support services. Once my health information has been shared with Gilead, federal privacy laws may no longer protect it. This means that Gilead can give it to others, such as the Food and Drug Administration (FDA), to learn if the Letairis REMS Program is being run properly as required by law. I understand that my pharmacy may receive payment in connection for disclosing my health information to Gilead for the purposes allowed under this authorization. I may also cancel my permission at any time by writing a letter to Gilead and faxing to 1-888-882-4035 or by calling 1-866-664-5327. If I cancel, Gilead will stop using or sharing my information for the reasons listed above, except as required by law to end my participation in the Letairis REMS Program. If I am a female and not enrolled in the Letairis REMS Program, I will no longer be able to receive Letairis. If I do not sign this form, I understand my eligibility for health plan benefits and treatment by my doctor will not change. I am allowed a copy of this signed agreement. My written permission ends 10 years from the date I signed it.

<b>REQUIRED FOR ALL PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
----------------------------------	---	-------------

## 4 Female Patient Agreement

For all Females: I acknowledge that I have been counseled that Letairis is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).

For Females Who Can Get Pregnant: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects. I have read the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant*. I understand that I will be contacted by Gilead and/or its agents and contractors to receive counseling on the risk of serious birth defects and the importance of not becoming pregnant, ensure that I have completed pregnancy testing before I start Letairis, monthly before each refill, and for 1 month after stopping Letairis, and obtain information about my pregnancy, if I become pregnant.

For Pre-Pubertal Females: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects, and that I have read the *Letairis Medication Guide*. Parent or guardian must sign below.

<b>REQUIRED FOR ALL FEMALE PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
---	---	-------------

## 5 Prescriber Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Phone: (\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_) \_\_\_\_\_ NPI #: \_\_\_\_\_

Office Contact (First and Last Name): \_\_\_\_\_ E-mail: \_\_\_\_\_

## 6 Prescription

**LETAIRIS:**  5 mg tablets (30 tablets)  10 mg tablets (30 tablets)  PO  QD Refills: \_\_\_\_\_

Instructions: \_\_\_\_\_

Ship to:  Patient Home (address listed above)  Prescriber Office (address listed above)  Other  
(please indicate below)

Name: \_\_\_\_\_ Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Phone: (\_\_\_\_) \_\_\_\_\_

## 7 Statement of Medical Necessity

**Diagnosis: Pulmonary Arterial Hypertension** (This is for insurance purposes only, not to suggest approved uses or indications. Please select one category below.)

Familial (ICD 416.0)  Idiopathic (ICD 416.0)

Scleroderma (ICD 710.1)  HIV (ICD 042 \_\_\_\_\_)

Lupus (ICD 710.0)  Portal Hypertension (ICD 572.3)

Congenital Heart Defects (ICD 745. \_\_\_\_\_ )  Other: \_\_\_\_\_ (ICD \_\_\_\_\_)

## 8 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below. Only 1 box should be checked. (Please see definitions of these terms on the following page)

### Female of Reproductive Potential

Has a negative pregnancy test been confirmed prior to prescribing Letairis?

Yes

No

OR

### Female of Non-Reproductive Potential (choose one below)

Pre-Pubertal Female

Post-Menopausal Female

Other medical reasons for permanent, irreversible infertility

I certify that for female patients, I have provided the appropriate counseling and Letairis REMS materials, and I will continue to fulfill my obligations under the Letairis REMS Program as outlined on page 2 of this form.

I authorize *LabSync* to order laboratory tests and receive laboratory results on my behalf for patients enrolled in the Letairis REMS Program and *LabSync*.

By signing, I certify that the above therapy is medically necessary.

<b>REQUIRED FOR ALL PRESCRIBERS</b>	Prescriber Signature: X	Date:
-------------------------------------	----------------------------	-------

## 8 Prescriber Authorization (continued)

### Definitions

#### Females of Reproductive Potential

- Females of Reproductive Potential include girls who have entered puberty and all women who have a uterus and have not passed through Menopause (as defined below).
- For the purposes of REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

#### Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
- Post-Menopausal Females: Females who have passed through Menopause (as defined below)
- Other medical reasons for permanent, irreversible infertility

#### Menopause

Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or postsurgical from bilateral oophorectomy.

### Prescriber obligations under the Letairis REMS Program

#### For All Females

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Letairis is available only through a restricted distribution program under an FDA-required REMS.
- I will evaluate the patient and agree to document any change in reproductive potential status by submitting a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

#### For Females of Reproductive Potential

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* with the patient (and parent/guardian when appropriate).
- I will order and review pregnancy tests prior to initiation of Letairis treatment, monthly during treatment, and for 1 month after stopping treatment in accordance with the Letairis REMS Program.

#### For Pre-Pubertal Females

- I acknowledge that I have counseled the patient and parent/guardian on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* with the patient and parent/guardian.
- I will evaluate the patient's reproductive potential status, verify reproductive potential status annually for Pre-Pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive potential status on a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

## 9 Fax this enrollment form and all patient insurance information, including drug benefit cards (front and back), to 1-888-882-4035.

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call 1-866-664-5327 for more information about the Letairis REMS Program.

Please see accompanying patient Medication Guide and full Prescribing Information, including **BOXED WARNING**.

This form is part of an FDA-approved REMS.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0019 OCTOBER 2015  
Letairis and LabSync are registered trademarks of Gilead Sciences, Inc. Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.

# Letairis Patient Enrollment and Consent Form

**FOR VA USE ONLY**

Fax this form and all patient insurance information, including drug benefit cards (front and back), to:  
1-888-882-4035

## 1 Specialty Pharmacy

Select a preferred Certified Pharmacy:

Accredo

## 2 Patient Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Birthdate: \_\_\_\_/\_\_\_\_/\_\_\_\_ Gender:  M  F Preferred Time to Contact:  Day  Evening  
Phone: (\_\_\_\_) \_\_\_\_\_ Alternate Phone: (\_\_\_\_) \_\_\_\_\_ E-mail: \_\_\_\_\_  
Alternate Contact Name: \_\_\_\_\_ Phone: (\_\_\_\_) \_\_\_\_\_  
Relationship: \_\_\_\_\_

## 3 Written Permission to Share Information

I allow Veterans Health Care Administration ("VA"), my specialty pharmacy or pharmacies, and my health plans to share personal and medical information about me to Gilead and its agents and contractors ("Gilead"). I allow Gilead to use and share this information to: 1) communicate with me, my healthcare providers and health plans about my medical care; 2) provide support services, including providing Letairis® (ambrisentan) to me; 3) learn how well Letairis, the Letairis REMS, or LEAP program is working; and 4) contact me so that I may receive educational materials about Letairis, the Letairis REMS, or the LEAP program.

Once my health information has been shared with Gilead, federal privacy laws may no longer protect it. This means that Gilead can give it to others, such as the Food and Drug Administration (FDA), to learn if the Letairis REMS Program is being run properly as required by law. I understand that my pharmacy may receive payment in connection for disclosing my health information to Gilead for the purposes allowed under this authorization. I may also cancel my permission at any time by writing a letter to Gilead and faxing to 1-888-882-4035 or by calling 1-866-664-5327. If I cancel, Gilead will stop using or sharing my information for the reasons listed above, except as required by law to end my participation in the Letairis REMS Program. If I am a female and not enrolled in the Letairis REMS Program, I will no longer be able to receive Letairis. If I do not sign this form, I understand my eligibility for health plan benefits and treatment by my doctor will not change. I am allowed a copy of this signed agreement. My written permission ends 10 years from the date I signed it.

<b>REQUIRED FOR ALL PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
----------------------------------	---	-------------

## 4 Female Patient Agreement

For all Females: I acknowledge that I have been counseled that Letairis is only available through a restricted distribution program under an FDA-required Risk Evaluation and Mitigation Strategy (REMS).

For Females Who Can Get Pregnant: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects. I have read the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant*. I understand that I will be contacted by Gilead and/or its agents and contractors to receive counseling on the risk of serious birth defects and the importance of not becoming pregnant, ensure that I have completed pregnancy testing before I start Letairis, monthly before each refill, and for 1 month after stopping Letairis, and obtain information about my pregnancy, if I become pregnant.

For Pre-Pubertal Females: I acknowledge that I have been counseled on the risks of Letairis, including the risk of serious birth defects, and that I have read the *Letairis Medication Guide*. Parent or guardian must sign below.

<b>REQUIRED FOR ALL FEMALE PATIENTS</b>	Patient or Parent/Guardian Signature: _____	Date: _____
---	---	-------------

## 5 Prescriber Information (PLEASE PRINT)

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ State License #: \_\_\_\_\_  
Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_  
Phone: (\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_) \_\_\_\_\_ NPI #: \_\_\_\_\_  
Office Contact (First and Last Name): \_\_\_\_\_ E-mail: \_\_\_\_\_

## 6 Prescription

LETAIRIS:  5 mg tablets (30 tablets)  10 mg tablets (30 tablets)  PO  QD Refills: \_\_\_\_\_

Instructions: \_\_\_\_\_

Ship to:  Patient Home (address listed above)  Prescriber Office (address listed above)  Other (please indicate below)

Name: \_\_\_\_\_ Address: \_\_\_\_\_

City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_ Phone: \_\_\_\_\_  
(\_\_\_\_) \_\_\_\_\_

## 7 Statement of Medical Necessity

**Diagnosis: Pulmonary Arterial Hypertension** (This is for insurance purposes only, not to suggest approved uses or indications. Please select one category below.)

Familial (ICD 416.0)  Idiopathic (ICD 416.0)

Scleroderma (ICD 710.1)  HIV (ICD 042 \_\_\_\_\_)

Lupus (ICD 710.0)  Portal Hypertension (ICD 572.3)

Congenital Heart Defects (ICD 745. \_\_\_\_\_)  Other: \_\_\_\_\_ (ICD \_\_\_\_\_)

## 8 Prescriber Authorization

For female patients, please indicate the patient's current reproductive status below. Only 1 box should be checked. (Please see definitions of these terms on the following page)

### Female of Reproductive Potential

Has a negative pregnancy test been confirmed prior to prescribing Letairis?

Yes

No

OR

### Female of Non-Reproductive Potential (choose one below)

Pre-Pubertal Female

Post-Menopausal Female

Other medical reasons for permanent, irreversible infertility

I certify that for female patients, I have provided the appropriate counseling and Letairis REMS materials, and I will continue to fulfill my obligations under the Letairis REMS Program as outlined on page 2 of this form.

By signing, I certify that the above therapy is medically necessary.

<b>REQUIRED FOR ALL PRESCRIBERS</b>	Prescriber Signature: X	Date:
-------------------------------------	----------------------------	-------

## 8 Prescriber Authorization (continued)

### Definitions

#### Females of Reproductive Potential

- Females of Reproductive Potential include girls who have entered puberty and all women who have a uterus and have not passed through Menopause (as defined below).
- For the purposes of REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

#### Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential
- Post-Menopausal Females: Females who have passed through Menopause (as defined below)
- Other medical reasons for permanent, irreversible infertility

### Menopause

Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or postsurgical from bilateral oophorectomy.

### Prescriber obligations under the Letairis REMS Program

#### For All Females

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) that Letairis is available only through a restricted distribution program under an FDA-required REMS.
- I will evaluate the patient and agree to document any change in reproductive potential status by submitting a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

#### For Females of Reproductive Potential

- I acknowledge that I have counseled the patient (and parent/guardian when appropriate) on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* and the *Letairis REMS Program Guide for Females Who Can Get Pregnant* with the patient (and parent/guardian when appropriate).
- I will order and review pregnancy tests prior to initiation of Letairis treatment, monthly during treatment, and for 1 month after stopping treatment in accordance with the Letairis REMS Program.

#### For Pre-Pubertal Females

- I acknowledge that I have counseled the patient and parent/guardian on the risks of Letairis, including the risk of serious birth defects, and that I have reviewed the *Letairis Medication Guide* with the patient and parent/guardian.
- I will evaluate the patient's reproductive potential status, verify reproductive potential status annually for Pre-Pubertal Females who are at least 8 years of age and older, and agree to report any change in reproductive potential status on a *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form* within 10 business days of becoming aware of the change.

## 9 Fax this enrollment form and all patient insurance information, including drug benefit cards (front and back), to 1-888-882-4035.

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call **1-866-664-5327** for more information about the Letairis REMS Program.

Please see accompanying patient Medication Guide and full Prescribing Information, including **BOXED WARNING**.

This form is part of an FDA-approved REMS.



© 2015 Gilead Sciences, Inc. All rights reserved. REMS-LET-0020 OCTOBER 2015  
Letairis are registered trademarks of Gilead Sciences, Inc. Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc.

# Letairis Risk Evaluation and Mitigation Strategy (REMS) Program Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form

Fax form to: 1-888-882-4035

Complete this form to:

1. Change the reproductive status of any female patient, or
2. Complete the annual verification of reproductive potential status for Pre-Pubertal Females, 8 years of age or older

**Prescriber must complete this form within 10 business days of awareness of the change in reproductive potential status.**

## 1 Patient Information (PLEASE PRINT)

Patient Letairis REMS ID: \_\_\_\_\_

First Name: \_\_\_\_\_ Middle Initial: \_\_\_\_\_ Last Name: \_\_\_\_\_

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Birthdate: \_\_\_\_/\_\_\_\_/\_\_\_\_ Phone: (\_\_\_\_) \_\_\_\_\_

## 2 Prescriber Information (PLEASE PRINT)

Office Contact and E-mail Address: \_\_\_\_\_

First Name: \_\_\_\_\_ Last Name: \_\_\_\_\_ State License #: \_\_\_\_\_

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ ZIP: \_\_\_\_\_

Phone: (\_\_\_\_) \_\_\_\_\_ Fax: (\_\_\_\_) \_\_\_\_\_ NPI #: \_\_\_\_\_

---

### **Definitions of Reproductive Potential Status:**

#### Females of Reproductive Potential

- Females of Reproductive Potential include girls who have entered puberty and all women who have a uterus and have not passed through Menopause (as defined below).
- For the purposes of this REMS, puberty includes those girls who are at least Tanner Stage 3 and have not yet had a menses (premenarchal).

#### Females of Non-Reproductive Potential

- Pre-Pubertal Females: Females who are at Tanner Stages 1 and 2 are not considered to be of reproductive potential.
- Post-Menopausal Female: Females who have passed through Menopause (as defined below).
- Other medical reasons for permanent, irreversible infertility.

#### Menopause

Menopause is defined as 12 months of spontaneous amenorrhea (not amenorrhea induced by a medical condition or medical therapy) or post-surgical from bilateral oophorectomy.

**3 Please select the most appropriate reason for submitting this form.**

**Change in Status**

- **Based on definitions of reproductive potential status, patient is (please check one):**

Female of Reproductive Potential

Female of Non-Reproductive Potential – Patient is pre-pubertal

Female of Non-Reproductive Potential – Patient is post-menopausal

Female of Non-Reproductive Potential – Other medical reasons for permanent, irreversible infertility

- **Reason for change in classification (please check one):**

Physiological transition

Medical/surgical (please specify): \_\_\_\_\_

Other (please specify): \_\_\_\_\_

**Annual Verification**

Patient remains a Pre-Pubertal Female (8 years of age or older)

<b>REQUIRED</b>	<b>By signing, I certify that the patient's reproductive potential status and reason for submitting this form are accurately noted above.</b> Prescriber Signature: X	Date:
-----------------	---	-------

Please visit [www.letairisrems.com](http://www.letairisrems.com) or call 1-866-664-5327 for more information about the Letairis REMS Program.

This form is part of an FDA-approved REMS.



### **The Letairis Risk Evaluation and Mitigation Strategy (REMS) Program**

A Risk Evaluation and Mitigation Strategy is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.

The purpose of the Letairis REMS Program is to:

- Inform prescribers, patients, and pharmacists about the risk of serious birth defects and safe-use conditions for Letairis
- Minimize the risk of fetal exposure and adverse fetal outcomes in Females of Reproductive Potential prescribed Letairis
  - Females who are pregnant must not be prescribed Letairis
  - Females taking Letairis must not become pregnant

**copyright information to be inserted here in final layout version— REMS-LET-0022 OCTOBER 2015**

[IMPORTANT SAFETY](#)      [INFORMATION](#)      [FULL](#)  
[PRESCRIBING INFORMATION](#)      [MEDICATION GUIDE](#)

FOR PRESCRIBERS (ANNOTATED TEXT...WILL NOT APPEAR ON LIVE SITE)

**Download Letairis REMS Materials >**

In order to ensure that Letairis is prescribed and taken safely, Gilead has worked with the FDA to develop materials for the Letairis REMS Program to inform prescribers and patients about the risk of serious birth defects.

**Letairis REMS Program Prescriber Materials**

[\*Prescriber Guide to the Letairis REMS Program\*](#)

[\*Prescriber Enrollment and Agreement Form\*](#)

[\*Patient Enrollment and Consent Form\*](#)

[\*Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form\*](#)

**Letairis REMS Program Patient Education Materials**

[\*Letairis REMS Program Guide for Females Who Can Get Pregnant\*](#)

[Get ADOBE® READER®](#)

**Overview of the Letairis REMS Program**

- Prescribers must enroll in the Letairis REMS Program and comply with the Letairis REMS Program requirements to prescribe Letairis
- All female patients must enroll in the Letairis REMS Program to receive Letairis
- Prescribers must educate and counsel Females of Reproductive Potential and Pre-Pubertal Females as described in the *Prescriber Guide to the Letairis REMS Program*. The parent/guardian of the Pre-Pubertal Female must also be educated and counseled on the risks of Letairis.
- Required pregnancy testing for Females of Reproductive Potential prior to writing a prescription for Letairis and monthly thereafter, including 1 month after stopping treatment with Letairis
- Letairis is only available through a restricted distribution program

**Changes to the Letairis REMS Program (October 2014)**

- New definition of Female of Non-Reproductive Potential
- Revised form: *Change in Reproductive Potential Status and Pre-Pubertal Annual Verification Form*

- **The following is a list of participating Certified Pharmacies:**

[Accredo](#)

[Aetna Specialty Pharmacy](#)

[CIGNA Tel-Drug](#)

[CuraScript](#)

[CVS Caremark](#)

[Exactus Pharmacy Solutions](#)

[Kaiser Specialty Pharmacy](#)

[OptumRx](#)

[RightSource Specialty Pharmacy](#)

[Walgreens Specialty Pharmacy](#)

[Home](#)

[Privacy Policy](#)

[Terms of Use](#)

[Contact Us](#)

copyright information to be inserted here in final layout version— REMS-LET-0022 OCTOBER 2015

**IMPORTANT SAFETY INFORMATION   FULL PRESCRIBING INFORMATION  
MEDICATION GUIDE  
FOR PATIENTS   (ANNOTATED TEXT... WILL NOT APPEAR ON LIVE SITE)**

**Welcome to the Letairis Risk Evaluation and Mitigation Strategy Program**

**What is the Letairis REMS Program?**

Because of the risk of serious birth defects, the FDA has required a special program called a Risk Evaluation and Mitigation Strategy (REMS) for Letairis. The purpose of the Letairis REMS Program is to make sure the benefits of Letairis outweigh the risks. All females must enroll in the Letairis REMS Program to receive Letairis; however, specific requirements apply to females who can get pregnant.

**For Female Patients to receive Letairis:**

- 1) You must talk with your doctor to ensure the benefits outweigh the risks of Letairis
- 2) You must agree to all of the requirements of the Letairis REMS Program. For women who can get pregnant, these requirements include monthly pregnancy tests and use of appropriate birth control while taking Letairis and for 1 month after stopping Letairis
- 3) Your doctor will enroll you in the Letairis REMS Program
- 4) Your prescription will be mailed to you from a Certified Pharmacy that you and your doctor will choose

For women who can get pregnant, learn more about the Letairis REMS Program.  
Download this helpful guide.


**Get ADOBE® READER®**

**[Home](#)**

**[Privacy Policy](#)**

**[Terms of Use](#)**

**[Contact Us](#)**



**copyright information to be inserted here in final layout  
version— REMS-LET-0022 OCTOBER 2015**

